Thus, loss of ERF activity by rare genomic loss-of-function mutations or by competition with the TMPRSS2-ERG oncogenic product leads to activation of the androgen receptor pathway and prostate cancer [79]. The gene discussed is AR; the disease is prostate carcinoma.